Company: EUDAW
Filing Date: 2025-11-18
Form Type: 424B5
Source: 0001493152-25-024074
Chunk: 0

Company: EUDA Health Holdings Ltd
Filing Date: 2025-11-18
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-282723

PROSPECTUS SUPPLEMENT NO. 2

(To Prospectus dated November 4, 2024)

<div align='center'>EUDA HEALTH HOLDINGS LIMITED</div>

We previously entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”), dated August 1, 2025, which was amended on each of September 19, 2025, October 2, 2025 and November 7, 2025, with Indigo Capital LP, an accredited investor (the “Investor”), pursuant to which we agreed to issue and sell to the Investor, from time to time, one or more convertible promissory notes (the “Convertible Notes”) in amounts not to exceed an aggregate principal amount of US$10,000,000. Pursuant to our prospectus, dated November 4, 2024 (the “Base Prospectus), we filed a prospectus supplement on August 8, 2025 (the “August Prospectus Supplement”) that included up to 5,000,000 Ordinary Shares, issuable from time to time upon conversion of the Convertible Notes and in lieu of cash payments of interest payable on the Convertible Notes. As of the date of this prospectus supplement, we have sold and issued to the Investor Convertible Notes in an aggregate principal amount of $1,000,000, and in connection with the conversion of these Convertible Notes, we have issued to the Investor an aggregate of 692,729 Ordinary Shares.

The purpose of this prospectus supplement is to terminate the continuous offering of the Convertible Notes and Ordinary Shares issuable in connection with the conversion of the Convertible Notes under the Base Prospectus and the August Prospectus Supplement. We will not make any additional sales of Convertible Notes under the Purchase Agreement and therefore will not issue additional shares in connection with any conversion of the Convertible Notes under the August Prospectus Supplement.

Unless
otherwise indicated in this prospectus supplement or the context otherwise requires, all references to “we,” “us,”
“our,” “the Company,” and “EUDA” refer to EUDA Health Holdings Limited and its subsidiaries.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this